The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway

Experimental Cell Research

Volumn 252, Issue 1, 1999, Pages 211-223

  Rao, Sharmila ^a   Gray Bablin, Julie ^a   Herliczek, Thaddeus W ^a   Keyomarsi, Khandan ^a,b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

cAMP; CDKs; Cell cycle; CKIs; p21; PKA

Indexed keywords

3 METHYLXANTHINE; CHOLERA TOXIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; MEVINOLIN; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROTEIN P21; PROTEIN P27;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GENE CONTROL; GENE INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

EID: 0033544007     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4620     Document Type: Article

References (76)

1. Sherr C. J. Cancer cell cycles. Science. 274:1996;1672-1677.
2. Sherr C. J. G1 phase progression: Cycling on cue. Cell. 79:1994;551-555.
3. Elledge S. J. Cell cycle checkpoints: Preventing an identity crisis. Science. 274:1996;1664-1671.
4. Nasmyth K. Viewpoint: Putting the cell cycle in order. Science. 274:1996;1643-1651.
5. Elledge S. J., Harper J. W. Cdk inhibitors; On the threshold of checkpoints and development. Curr. Opin. Cell Biol. 6:1994;847-852.
6. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
7. Harper J. W., Elledge S. J. CDK inhibitors in development and cancer. Curr. Opin. Genes Dev. 6:1996;56-64.
8. Harper J. W. Cyclin dependent kinase inhibitors. Cancer Surv. 29:1997;91-108.
9. Elledge S. J., Winston J., Harper J. W. A question of balance: The role of cyclin-kinase inhibitors in development and tumorigenesis. Tr. Cell Biol. 6:1996;388-392.
10. El-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mrcer W. E., Kinzler K. W., Vogelstein B. WAF-1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
11. Gu Y., Turck C. W., Morgan D. O. Inhibition of cdk2 activity in vivo by an associated 20K regulatory subunit. Nature. 366:1993;707-710.
12. Harper J. W., Adami G. R., Wei N., Keyomarsi K., Elledge S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 75:1993;805-816.
13. Xiong Y., Hannon G. J., Zhang G. J., Gasso D., Kobayashi R., Beach D. p21, a universal inhibitor of cyclin kinases. Nature. 366:1993;710-704.
14. Noda A. F., Ning Y., Venable S., Pereira-Smith O. M., Smith J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell. Res. 211:1994;90-98.
15. Jiang H., Fisher P. B. Use of a sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells. Mol. Cell. Diff. 3:1993;285-299.
16. Wu H., Wade M., Krall L., Grisham J., Xiong Y., Van Dyke T. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev. 10:1996;245-260.
17. Dulic V., Kaufman W. K., Wilson S., Tlisty T. D., Lees E., Harper J. W., Elledge S. J., Reed S. I. p53-dependent inhibition of cyclin dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell. 76:1994;1013-1023.
18. Michieli P., Chedid M., Lin D., Pierce J. H., Mercer W. E., Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54:1994;3391-3395.
19. Sheikh M. S., X. L., Chen J., Shao Z., Ordonez J. V., Fontana J. A. Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways. Oncogene. 9:1994;3407-3415.
20. Elbendary A., Berchuck A., Davis P., Havrilesky L., Bast J., R. C., Iglehart J. D., Marks J. R. Transforming growth factor B1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Diff. 5:1994;1301-1307.
21. Gray-Bablin J., Rao S., Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle independent fashion. Cancer Res. 57:1997;604-609.
22. Rao S., Lowe M., Herliczek T., Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells in through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene. 17:1998;2393-2402.
23. Polyak K., Lee M.-H., Erdjument-bromage H., Tempst P., Massaague J. Cloning of p27KIP1, a cyclin-dependent kinase inhibitor and potential mediator of extracellular antimotogenic signals. Cell. 78:1994;59-66.
24. Polyak K., Kato J.-Y., Soloman M. I., Sherr C. J., Massague J., Roberts J. M., Koff A. p27KIP1, a cyclin-cdk inhibitor, links transforming growth factorβ and contact inhibition to cell cycle arrest. Genes Dev. 8:1994;9-22.
25. Toyoshima H., Hunter T. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
26. Hengst L., Dulic V., Slingerland J. M., Lees E., Reed S. I. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc. Natl. Acad. Sci. USA. 91:1994;5291-5295.
27. Hengst L., Reed S. I. Translational control of p27Kip1 accumulation during the cell cycle. Science. 271:1996;1861-1864.
28. Pagano M., Tam S. W., Theodoras A. M., Beer-Romero P., Del Sal G., Chau V., Yew R. P., Draetta G. F., Rolfe M. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
29. Starzec A. B., Spanakis E., Nehme A., Salle V., Veber N., Mainguene C., Planchon P., Valette A., Prevost G., Israel L. Proliferative responses of epithelial cells to 8-bromo-cyclic AMP and to a phorbol ester change during breast pathogenesis. J. Cell. Phys. 161:1994;31-38.
30. Mann D. J., Higgins T., Jones N. C., Rozengurt E. Differential control of cyclins D1 and D3 and the cdk inhibitor p27Kip1 by diverse signalling pathways in Swiss 3T3 cells. Oncogene. 14:1997;1759-1766.
31. Revillion F., Vandewalle B., Lassalle B., Lefebvre J. cAMP effect on extracellular matrix synthesis in human breast cancer cells. Cell Prol. 25:1992;633-642.
32. Agarwal K. C., Parks R. E. Forskolin: A potential antimetastatic agent. Int. J. Cancer. 32:1983;801-804.
33. Kip1) of cyclin-dependent kinase 4 activation. Cell. 79:1994;487-496.
34. Trepel J. B., Colamonici O. R., Kelly K., Schwab G., Watt R. A., Sausville E. A., Jaffe E. S., Neckers L. M. Transcriptional inactivatio of -myc and the transferrin receptor in dibutyryl cyclic AMP-treated HL-60 cells. Mol. Cell. Biol. 7:1987;2644-2648.
35. Slungaard A., Confer D. L., Schubach W. H. Rapid transcriptional down-regulation of c-myc expression during cyclic adenosine monophosphate-promoted differentiation of leukemic cells. J. Clin. Invest. 79:1987;1542-1547.
36. Bang Y. J., Kim S. J., Danielpour D., O'Reilly M. A., Kim K. Y., Myers C. E., Trepel J. B. Cyclic AMP induces transforming growth factor β2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line PC-3. Proc. Natl. Acad. Sci. USA. 89:1992;3556-3560.
37. Sewing A., Burger C., Brusselbach S., Schalk C., Lucibello F. C., Muller R. Human cyclin D1 encodes a labile nuclear protein whose synthesis is directly induced by growth factors and suppressed by cyclic AMP. Cell Sci. 104:1993;545-554.
38. Friessen A. J., Miskimins W. K., Miskimins R. Cyclin-dependent kinase inhibitor p27kip1 is expressed at high levels in cells that express a myelinating phenotype. J. Neuro. Res. 50:1987;373-382.
39. Vallejo, M., and Habener, J. F.1994Mechanisms of transcriptional regulation by cAMP. InTranscription: Mechanisms and Regulation, pp. 353-368, Raven Press, Ltd. New York.
40. Laurenza A., Sutkowski E. M., Seamon K. B. Forskolin: A specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action. Trends Pharmacol. Sci. 10:1989;442-447.
41. Viallet J., Sharoni Y., Frucht H., Jensen R. T., Minna J. D., Sausville E. A. Cholera toxin inhibits signal transduction by several mitogens and the in vitro growth of human small-cell lung cancer. J. Clin. Invest. 86:1990;1904-1912.
42. Drees M., Zimmermann R., Eisenbrand G. 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res. 53:1993;3058-3061.
43. Kaur G., Stetler-Stevenson M., Sebers S., Worland P., Sedlacek H., Myers C., Czech J., Naik R., Sausville E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by falvone L86-8275. J. Natl. Cancer Inst. 84:1992;1736-1740.
44. Lasa M., Chiloeches A., Garcia N., Montes A., Toro M. J. Lovastatin decreases prolactin and growth hormone gene expression in GH4C1 cells through a cAMP dependent mechanism. Mol. Cell. Endocrinol. 130:1997;93-100.
45. Ecay T. W., Valentich J. D. Lovastatin inhibits cAMP- and calcium-stimulated chloride secretion by T84 cells. Am. J. Physiol. 265:1993;C422-C431.
46. Kaczmarek D., Hohfeld T., Wambach G., Schror K. The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolaemia. A double-blind, placebo-controlled, prospective study. Eur. J. Clin. Pharmacol. 45:1993;451-457.
47. Retterstol K., Stuggard M., Gorbitz C., Ose L. Results of intensive long term treatment of familial hypercholesterolemia. Am. J. Cardiol. 78:1996;1369-1374.
48. Keyomarsi K., Sandoval L., Band V., Pardee A. B. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 51:1991;3602-3609.
49. Keyomarsi K. Synchronization of mammalian cells by lovastatin. Methods Cell Sci. 18:1996;109-114.
50. Terada Y., Inoshita S., Nakashima O., Yamada T., Kuwahara M., Sasaki S., Marumo F. Lovastatin inhibits mesangial cell proliferation via p27 Kip1. J. Am. Soc. Nephrol. 9:1998;2235-2243.
51. Hirai A., Nakamura S., Noguchi Y., Yasuda T., Kitagawa M., Tatsuno I., Oeda T., Tahara K., Terano T., Narumiya S., Kohn L. D., Saito Y. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem. 272:1997;13-16.
52. Lee S. J., Ha M. J., Lee J., Nguyen P. M., Choi Y. H., Pirnia F., Kang W.-K., Wang X.-F., Kim S.-J., Trepel J. B. Inhibition of the 3-hyroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21 in human prostatic carcinoma cells. J. Biol. Chem. 273:1998;10618-10623.
53. Arita Y., Buffolino P., Coppock D. L. Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc kinase activity. Exp. Cell Res. 242:1998;381-390.
54. Vogt A., Sun J., Qian Y., Hamilton A. D., Sebti S. M. The geranylygeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21 in a p53-independent manner. J. Biol. Chem. 272:1997;27224-27229.
55. Keyomarsi K., Conte D., Toyofuku W., Fox M. P. Deregulation of cyclin E in breast cancer. Oncogene. 11:1995;941-950.
56. Rogers K. V., Goldman P. S., Frizzell R. A., McKnight G. S. Regulation of C1-transport of T84 cell clones expressing a mutant regulatory subunit of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 87:1990;8975-8979.
57. Clegg C. H., Correll L. A., Cadd G. C., McKnight G. S. Inhibition of intracellular cAMP-dependent protein kinase using mutant genes of regulatory type I subunit. J. Biol. Chem. 262:1987;13111-13119.
58. Steinberg R. A., O'Farrell P. H., Fiedrich U., Coffino P. Mutations causing charge alterations in regulatory subunits of the cAMP-dependent protein kinase of cultured S49 lymphoma cells. Cell. 10:1977;381-391.
59. Ecay T. W., Valentich J. D. Lovastatin inhibits cAMP- and calcium-stimulated chloride secretion by T84 cells. Am. J. Physiol. 265:1993;C422-C431.
60. Alberi S., Dreiguss J., Raggenbass M. The oxytocin-induced inward current in bagal neurons of the rat is mediated by G protein activation but not by an increase in the intracellular calcium concentration. Eur. J. Neuro. 9:1997;2605-2612.
61. DiFrancesco D., Tortora P. Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature. 351:1991;145-147.
62. Nakamura T., Gold G. H. A cyclic nucleotide-gated conductance in olfactory receptor cilia. Nature. 325:1987;442-444.
63. Wiesner B., Weiner J., Middendorff R., Hagen V., Kaupp U. B., Weyand I. Cyclic nucleotide-gated channels on the flagellum control Ca2+ entry into sperm. J. Cell Biol. 142:1998;473-484.
64. Weyand I., Godde M., Fringe S., Weiner J., Altenhofen W., Hatt H., Kaupp U. B. Cloning and functional expression of a cyclic-nucleotide-gated channel from mammalian sperm. Nature. 368:1994;859-863.
65. Schecterson L. C., McKnight G. S. Role of cyclic adenosine 3′,5′-monophosphate-dependent protein kinase in hormone-stimulated β-endorphin secretion in AtT20 cells. Mol. Endocrinol. 5:1991;170-178.
66. Blagosklonny M. V., Wu G. S., Mura S., Eldeiry W. S. Proteosome dependent regulation of p21 expression. Biochem. Biophys. Res. Commun. 227:1996;564-569.
67. Pagano M. Cell cycle regulation by the ubiquitin pathway. FASEB J. 11:1997;1067-1075.
68. Rao S., Porter D. C., Chen X., Herliczek T., Lowe M., Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA. 96:1999;7797-7802.
69. Murray E. J., Bentley G. V., Grisanti M. S., Murray S. S. The ubiquitin-proteasome system and cellular proliferation and regulation in osteoblastic cells. Exp. Cell Res. 242:1998;460-469.
70. Inaba K., Morisawa S., Morisawa M. Proteasomes regulate the motility of salmonid fish sperm through modulation of cAMP-dependent phosphorylation of an outer arm dynein light chain. J. Cell Sci. 111:1998;1105-1115.
71. Gastel J. A., Roseboom P. H., Rinaldi P. A., Weller J. L., Klein D. C. Melatonin production: Proteasomal proteolysis in serotonin N-acetyltransferase regulation. Science. 279:1998;1358-1360.
72. Falco E. J., Koren G. Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin-proteasome pathway. Biochem. J. 328:1997;37-43.
73. Staub O., Gautschi I., Ishikawa T., Breitschopf K., Ciechanover A., Schild L., Rotin D. Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiqitination. EMBO J. 16:1997;6325-6336.
74. Realini C., Rechsteiner M. A proteasome activator subunit binds calcium. J. Biol. Chem. 270:1995;29664-29667.
75. LaBaer J., Garrett M. D., Stevenson L. F., Slingerland J., Sandhu C., Chou H. S., Fattaey A., Harlow E. New functional activities for the p21 family of cdk inhibitors. Genes Dev. 11:1997;847-862.
76. Font de Mora J., Uren A., Heidaran M., Santos E. Biological activity of p27kip1 and its amino- and carboxy-terminal domains in G2/M transition of Xenopus oocytes. Oncogene. 15:1997;2541-2551.